Creative Medical Technology Holdings (CELZ) Price to Sales (2017 - 2025)

Creative Medical Technology Holdings (CELZ) has reported Price to Sales for 9 consecutive years, with 868.85 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Price to Sales fell 15.15% year-over-year to 868.85 in Q4 2025; TTM through Jun 2026 was 642.77, a 9.43% increase from a year earlier, with the FY2025 full-year figure at 448.72, up 55.56% from the prior year.
• Price to Sales was 868.85 for Q4 2025 at Creative Medical Technology Holdings, down from 961.94 in the prior quarter.
• Over five years, Price to Sales peaked at 4060.14 in Q2 2021 and troughed at 84.97 in Q4 2021.
• A 5-year average of 1230.55 and a median of 992.97 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales plunged 99.96% in 2021 and jumped 912.99% in 2023, its largest moves.
• Over 5 years, Price to Sales stood at 84.97 in 2021, then jumped by 163.6% to 223.99 in 2022, then jumped by 842.37% to 2110.81 in 2023, then sank by 51.49% to 1024.0 in 2024, then decreased by 15.15% to 868.85 in 2025.
• The last three Price to Sales figures came in at 868.85 (Q4 2025), 961.94 (Q1 2025), and 1024.0 (Q4 2024), per Business Quant data.